Plant Advanced Technologies SA (ALPAT.PA)
EUR 11.7
(-2.5%)
EUR 11.7
(-2.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.78 Million EUR | -34.11% |
| 2022 | 10.29 Million EUR | 5.82% |
| 2021 | 9.72 Million EUR | 11.46% |
| 2020 | 8.72 Million EUR | 124.64% |
| 2019 | 3.88 Million EUR | 89197.32% |
| 2018 | 4350.49 EUR | 28.31% |
| 2017 | 3390.55 EUR | 5.66% |
| 2016 | 3209.06 EUR | 17.64% |
| 2015 | 2727.79 EUR | -13.51% |
| 2014 | 3153.83 EUR | -99.85% |
| 2013 | 2.16 Million EUR | 55.59% |
| 2012 | 1.38 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 6.78 Million EUR | -34.11% |
| 2023 Q4 | 6.78 Million EUR | 0.0% |
| 2023 Q2 | 6.8 Million EUR | 0.0% |
| 2022 FY | 10.29 Million EUR | 5.82% |
| 2022 Q2 | 9.59 Million EUR | 0.0% |
| 2022 Q4 | 10.29 Million EUR | 0.0% |
| 2021 Q4 | 9.72 Million EUR | 0.0% |
| 2021 FY | 9.72 Million EUR | 11.46% |
| 2021 Q2 | 8.88 Million EUR | 0.0% |
| 2020 Q2 | 5.55 Million EUR | 0.0% |
| 2020 FY | 8.72 Million EUR | 124.64% |
| 2020 Q4 | 5.47 Million EUR | 0.0% |
| 2019 Q2 | 4.79 Million EUR | 0.0% |
| 2019 FY | 3.88 Million EUR | 89197.32% |
| 2019 Q4 | 3.88 Million EUR | 0.0% |
| 2018 Q2 | 4706.97 EUR | 0.0% |
| 2018 FY | 4350.49 EUR | 28.31% |
| 2018 Q4 | 4350.49 EUR | 0.0% |
| 2017 Q2 | 3652.50 EUR | 0.0% |
| 2017 FY | 3390.55 EUR | 5.66% |
| 2017 Q4 | 3390.55 EUR | 0.0% |
| 2016 Q2 | 3372.86 EUR | 0.0% |
| 2016 FY | 3209.06 EUR | 17.64% |
| 2016 Q4 | 3209.06 EUR | 0.0% |
| 2015 FY | 2727.79 EUR | -13.51% |
| 2015 Q4 | 2727.79 EUR | 0.0% |
| 2015 Q2 | 3190.77 EUR | 0.0% |
| 2014 Q4 | 3153.83 EUR | 0.0% |
| 2014 Q2 | 2800.07 EUR | 0.0% |
| 2014 FY | 3153.83 EUR | -99.85% |
| 2013 FY | 2.16 Million EUR | 55.59% |
| 2013 Q4 | 2.16 Million EUR | 0.0% |
| 2012 FY | 1.38 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | 1.876% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 94.825% |
| Adocia SA | 31.87 Million EUR | 78.719% |
| Aelis Farma SA | 13.08 Million EUR | 48.147% |
| Biophytis S.A. | 15.84 Million EUR | 57.206% |
| Advicenne S.A. | 24.37 Million EUR | 72.177% |
| genOway Société anonyme | 14.45 Million EUR | 53.094% |
| IntegraGen SA | 5.97 Million EUR | -13.421% |
| Medesis Pharma S.A. | 6.42 Million EUR | -5.542% |
| Neovacs S.A. | 3.71 Million EUR | -82.708% |
| NFL Biosciences SA | 3.62 Million EUR | -87.322% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -104.898% |
| Sensorion SA | 13.22 Million EUR | 48.724% |
| Theranexus Société Anonyme | 5.01 Million EUR | -35.209% |
| TME Pharma N.V. | 2.78 Million EUR | -143.531% |
| Valbiotis SA | 13.7 Million EUR | 50.523% |
| TheraVet SA | 1.48 Million EUR | -356.726% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 66.864% |
| argenx SE | 402.79 Million EUR | 98.316% |
| BioSenic S.A. | 32.26 Million EUR | 78.979% |
| Celyad Oncology SA | 9.97 Million EUR | 32.027% |
| DBV Technologies S.A. | 38.74 Million USD | 82.495% |
| Galapagos NV | 1.56 Billion EUR | 99.566% |
| Genfit S.A. | 105.92 Million EUR | 93.597% |
| GeNeuro SA | 20.13 Million EUR | 66.324% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | 21.245% |
| Innate Pharma S.A. | 132.29 Million EUR | 94.873% |
| Inventiva S.A. | 101.59 Million EUR | 93.324% |
| MaaT Pharma SA | 22.46 Million EUR | 69.809% |
| MedinCell S.A. | 77.77 Million EUR | 91.279% |
| Nanobiotix S.A. | 95.74 Million EUR | 92.916% |
| Onward Medical N.V. | 25.69 Million EUR | 73.607% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 73.006% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 88.52% |
| Oxurion NV | 19.73 Million EUR | 65.635% |
| Pharming Group N.V. | 228.28 Million EUR | 97.029% |
| Poxel S.A. | 53.9 Million EUR | 87.417% |
| GenSight Biologics S.A. | 34.72 Million EUR | 80.47% |
| Transgene SA | 26.51 Million EUR | 74.423% |
| Financière de Tubize SA | 123.65 Million EUR | 94.515% |
| UCB SA | 6.56 Billion EUR | 99.897% |
| Valneva SE | 341.14 Million EUR | 98.012% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -49.161% |